Hiroshima Study: Tooth Count Predicts Pancreatic Survival

Researchers at Hiroshima University have found that natural tooth count is an independent prognostic indicator of long-term survival after surgical resection for pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. Published in the Journal of Hepato-Biliary-Pancreatic Sciences on 23 April 2026 and reported by Dental Tribune International on 10 September, the study strengthens the growing evidence base linking oral health to systemic disease outcomes in oncology.

The retrospective study, led by co-author Dr Kenichiro Uemura (Hiroshima University Graduate School of Biomedical and Health Sciences), included 339 patients who underwent pancreatic resection at Hiroshima University Hospital. Patients with fewer natural teeth showed significantly shorter overall survival, with the association remaining significant after adjustment for established prognostic factors. Uemura highlighted the marked survival gap: patients with more natural teeth lived almost two years longer than those with fewer teeth. Masticatory function, assessed by posterior occlusion, was not independently linked to survival, suggesting tooth count may reflect cumulative health influences including chronic inflammation, frailty, nutrition and long-term systemic vulnerability.

The study builds on previous research linking periodontal pathogens such as Porphyromonas gingivalis to pancreatic carcinogenesis and tumour progression. Uemura’s team plans to validate findings in larger, multicentre and international studies. The long-term goal is to integrate oral health assessment into personalised risk stratification and perioperative management for pancreatic cancer patients. The findings tie into a rapidly growing oral-systemic health research theme reshaping dental commercial opportunity across cancer supportive care, prosthetics and preventive interventions.

The commercial signal is a maturing oral-systemic health category increasingly relevant to oncology supportive care and prognostic assessment. Growing evidence for tooth retention as a cumulative health indicator strengthens commercial rationale for preventive dentistry, prosthetics and implants. Expect Straumann, Nobel Biocare (Envista), Zimmer Biomet, Dentsply Sirona and preventive oral care specialists Colgate-Palmolive, Procter & Gamble and GlaxoSmithKline to sharpen positioning through 2027.

For the latest updates and in-depth insights into the world of Dentistry, including breakthrough treatments, industry trends, and regulatory news, contact Albert Baines today!